The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on Alzheimer's Disease meeting in San Francisco.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
